Sanofi is expanding its neuroscience drug pipeline through the $470 million acquisition(Opens in a new window) of Vigil Neuroscience, a clinical-stage biotech with a...
Alzheimer’s disease is currently diagnosed with expensive medical imaging or invasive methods that require a spinal tap. Patients now have an alternative. The FDA...